Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Clene Nanomedicine
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05299658CT.gov An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS | — | Active Not Recruiting | — | — | — |
NCT04414345CT.gov HEALEY ALS Platform Trial - Regimen C CNM-Au8 | — | Completed | — | — | — |
NCT04297683CT.gov HEALEY ALS Platform Trial - Master Protocol | — | Recruiting | — | — | — |
NCT04098406CT.gov Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS) | — | Completed | — | — | — |
NCT05281484CT.gov Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS | — | No Longer Available | — | — | — |
NCT06408727CT.gov Intermediate Expanded Access Protocol CNMAu8.EAP04 | — | Temporarily Not Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyotrophic Lateral Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cnm-Au8 (this asset) | Clene Nanomedicine | P2/3 | B · 60 |
| Taurursodiol | Amylyx Pharmaceuticals Inc. | P3 | BBB |
| Tofersen | Biogen | P4 | BBB |
| Riluzole | AB Science | P4 | BB |
| Mexiletine | Bjorn Oskarsson, MD | P4 | BB |
| Diacetyl(N(4)-Methylthiosemicarbazonato) Copper (Ii) | Collaborative Medicinal Development Pty Limited | P2/3 | BB |
| mt-1186 | Tanabe Pharma Corporation | P3 | BB |
| Mci-186 | Tanabe Pharma Corporation | P3 | BB |
| Kns-760704 | Knopp Biosciences | P3 | BB |
+42 more in the Amyotrophic Lateral Sclerosis cohort
Other indications for Cnm-Au8
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P2/3 | B · 60 |
| Optic Nerve Disorder | — | P2 | CCC · 53 |
| Multiple Sclerosis | — | Unk | D · 28 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cnm-Au8 in Amyotrophic Lateral Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cnm-au8-amyotrophic-lateral-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →